Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Cost-effectiveness of cervical cancer prevention.

Esselen KM, Feldman S.

Clin Obstet Gynecol. 2013 Mar;56(1):55-64. doi: 10.1097/GRF.0b013e3182823797. Review.

PMID:
23318570
2.

Projected cost-effectiveness of repeat high-risk human papillomavirus testing using self-collected vaginal samples in the Swedish cervical cancer screening program.

Östensson E, Hellström AC, Hellman K, Gustavsson I, Gyllensten U, Wilander E, Zethraeus N, Andersson S.

Acta Obstet Gynecol Scand. 2013 Jul;92(7):830-40. doi: 10.1111/aogs.12143. Epub 2013 Apr 22. Erratum in: Acta Obstet Gynecol Scand. 2013 Aug;92(8):994.

PMID:
23530870
3.

Cervical cancer screening and prevention in low-resource settings.

Bradford L, Goodman A.

Clin Obstet Gynecol. 2013 Mar;56(1):76-87. doi: 10.1097/GRF.0b013e31828237ac. Review.

PMID:
23337844
4.

Cervical cancer screening in high- and low-resource countries: implications and new developments.

Hoppenot C, Stampler K, Dunton C.

Obstet Gynecol Surv. 2012 Oct;67(10):658-67. doi: 10.1097/OGX.0b013e3182732375. Review.

PMID:
23112073
5.

[Effectiveness and health economic analysis of strategies on cervical cancer screening and early diagnosis and treatment].

Zhao FH, Chen JF, Gao XH, Gao LM, Liu QG, Liu ZH, Xu H, Ma JF, Ma L, Xu XL, Hu SY, Ning Y, Shi JF, Qiao YL.

Zhonghua Zhong Liu Za Zhi. 2012 Aug;34(8):632-6. doi: 10.3760/cma.j.issn.0253-3766.2012.08.017. Chinese.

PMID:
23159002
6.

Cervical cancer screening in low- and middle-income countries.

Ditzian LR, David-West G, Maza M, Hartmann B, Shirazian T, Cremer M.

Mt Sinai J Med. 2011 May-Jun;78(3):319-26. doi: 10.1002/msj.20263.

PMID:
21598259
7.

Cost effectiveness of human papillomavirus testing to augment cervical cancer screening in women infected with the human immunodeficiency virus.

Goldie SJ, Freedberg KA, Weinstein MC, Wright TC, Kuntz KM.

Am J Med. 2001 Aug;111(2):140-9.

PMID:
11498068
8.

Cost effectiveness of prophylactic HPV 16/18 vaccination in Finland: results from a modelling exercise.

Torvinen S, Nieminen P, Lehtinen M, Paavonen J, Demarteau N, Hahl J.

J Med Econ. 2010;13(2):284-94. doi: 10.3111/13696998.2010.485951.

PMID:
20482244
9.

Modeling cost-effectiveness of cervical cancer screening in Hungary.

Vokó Z, Nagyjánosi L, Margitai B, Kövi R, Tóth Z, László D, Kaló Z.

Value Health. 2012 Jan;15(1):39-45. doi: 10.1016/j.jval.2011.10.003.

10.
11.

The costs, clinical benefits, and cost-effectiveness of screening for cervical cancer in HIV-infected women.

Goldie SJ, Weinstein MC, Kuntz KM, Freedberg KA.

Ann Intern Med. 1999 Jan 19;130(2):97-107.

PMID:
10068381
12.

Cost-effectiveness analysis for Pap smear screening and human papillomavirus DNA testing and vaccination.

Chen MK, Hung HF, Duffy S, Yen AM, Chen HH.

J Eval Clin Pract. 2011 Dec;17(6):1050-8. doi: 10.1111/j.1365-2753.2010.01453.x. Epub 2011 Jun 16.

PMID:
21679279
13.

Does it matter? Discounting and its role in the cost-effectiveness of preventative interventions. The case of HPV vaccination.

Starkie Camejo H, Li X, Van Kriekinge G.

Public Health. 2015 Jul;129(7):989-92. doi: 10.1016/j.puhe.2015.02.028. Epub 2015 Mar 31. No abstract available.

14.

Cost-effectiveness analysis of prophylactic cervical cancer vaccination in Japanese women.

Konno R, Sasagawa T, Fukuda T, Van Kriekinge G, Demarteau N.

Int J Gynecol Cancer. 2010 Apr;20(3):385-92. doi: 10.1111/IGC.0b013e3181d189b8.

PMID:
20375802
15.

Cost-effectiveness analysis of HPV vaccination alongside cervical cancer screening programme in Slovenia.

Obradovic M, Mrhar A, Kos M.

Eur J Public Health. 2010 Aug;20(4):415-21. doi: 10.1093/eurpub/ckp208. Epub 2010 Jul 12.

PMID:
20624834
16.

A cost-utility analysis of adding a bivalent or quadrivalent HPV vaccine to the Irish cervical screening programme.

Dee A, Howell F.

Eur J Public Health. 2010 Apr;20(2):213-9. doi: 10.1093/eurpub/ckp141. Epub 2009 Oct 28.

PMID:
19864366
17.

How to screen for cervical cancer after HPV16/18 vaccination in The Netherlands.

Coupé VM, de Melker HE, Snijders PJ, Meijer CJ, Berkhof J.

Vaccine. 2009 Aug 13;27(37):5111-9. doi: 10.1016/j.vaccine.2009.06.043. Epub 2009 Jun 28.

PMID:
19567242
18.

Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine.

Goldie SJ, Kohli M, Grima D, Weinstein MC, Wright TC, Bosch FX, Franco E.

J Natl Cancer Inst. 2004 Apr 21;96(8):604-15.

PMID:
15100338
19.

Introducing HPV vaccine and scaling up screening procedures to prevent deaths from cervical cancer in Japan: a cost-effectiveness analysis.

Yamamoto N, Mori R, Jacklin P, Osuga Y, Kawana K, Shibuya K, Taketani Y.

BJOG. 2012 Jan;119(2):177-86. doi: 10.1111/j.1471-0528.2011.03036.x. Epub 2011 Jul 28.

20.

[Is early cervical cancer screening justified?].

Baldauf JJ, Fender M, Akladios CY, Velten M.

Gynecol Obstet Fertil. 2011 Jun;39(6):358-63. doi: 10.1016/j.gyobfe.2011.04.005. Epub 2011 May 20. Review. French.

PMID:
21600827

Supplemental Content

Support Center